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Abstract
Acute pulmonary embolism (PE) is the third most common cardiovascular cause of death after acute myocardial infarction and
stroke. Patients are, however, often under-treated due to the risks associated with systemic thrombolysis and surgical embolec-
tomy. Novel pharmacological and catheter-based treatment strategies show promise, but the data supporting their use in patients
are sparse. We therefore aimed to develop an in vivo model of acute PE enabling controlled evaluations of efficacy and safety of
novel therapies. Danish Landrace pigs (n¼ 8) were anaesthetized and mechanically ventilated. Two pre-formed autologous PEs
(PE1, PE2, 20 1 cm) were administered consecutively via the right external jugular vein. The intact nature and central location
were visualized in situ by magnetic resonance imaging (MRI). The hemodynamic and biochemical responses were evaluated at
baseline (BL) and after each PE by invasive pressure measurements, MRI, plus arterial and venous blood analysis. Pulmonary arterial
pressure increased after administration of the PEs (BL: 16.3 1.2, PE1: 27.6 2.9, PE2: 31.6 3.1 mmHg, BL vs. PE1: P¼ 0.0027,
PE1 vs. PE2: P¼ 0.22). Animals showed signs of right ventricular strain evident by increased end systolic volume (BL: 60.9 5.1,
PE1: 83.3 5.0, PE2: 99.4 6.5 mL, BL vs. PE1: P¼ 0.0005, PE1 vs. PE2: P¼ 0.0045) and increased plasma levels of Troponin T.
Ejection fraction decreased (BL: 58.9 2.4, PE1: 46.4 2.9, PE2: 37.3 3.5%, BL vs. PE1: p¼ 0.0008, PE1 vs. PE2: P¼ 0.009) with a
compensatory increase in heart rate preserving cardiac output and systemic blood pressure. The hemodynamic and biochemical
responses were comparable to that of patients suffering from intermediate-high-risk PE. This porcine model mirrors the anatomical
and physiologic changes seen in human patients with intermediate-high-risk PE, and may enable testing of future therapies for
this disease.
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Acute pulmonary embolism (PE) is a common disease with a
high mortality, making it the third most common cardiovas-
cular cause of death, surpassed only by acute myocardial
infarction and stroke.1,2
To optimize treatment, patients with acute PE are strati-
fied into groups of low-risk, intermediate-low-risk, inter-
mediate-high-risk, and high-risk of early mortality based
on clinical presentation, measures of right ventricular
(RV) strain, and systemic hemodynamic impairment.
Cornerstones in the treatment are anticoagulation therapy
in low-risk and intermediate-low-risk patients and thrombo-
lytic therapy in high-risk patients.3–5 However, thrombolysis
is contraindicated in one-third of the high-risk patients due
to the increased risk of bleeding.6 Even in patients screened
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for contraindications, systemic thrombolysis is associated
with a 3% risk of stroke and 13% risk of major bleeding.7
Today, the alternate treatment is emergency surgical embol-
ectomy, but co-morbidities often make these patients poor
candidates for major surgery, indicated by in-hospital mor-
tality rates at 30% for the procedure.8
The development of new treatment strategies is ongoing.
Newly developed catheter-directed therapies have shown
promise as a new treatment option by enabling effective
thrombus removal without the risks associated with stand-
ard treatment.9,10 Strategies of pharmacological unloading
and support of the RV during acute PE has also shown
promise.11,12 However, data supporting the use of these
novel treatment options in patients are sparse. Due to the
heterogeneous and acute nature of the disease, large clinical
trials are challenging to conduct. To investigate the efficacy
and safety of these novel pharmacological and catheter-
based treatment options, thorough controlled preclinical
studies are needed.
The majority of current experimental models of PE are
ex vivo.13 To evaluate efficacy and safety of novel treat-
ments in a setting comparable to human physiology, larger
in vivo animal models are needed. Such a model would
need to be comparable to the clinical presentation of
patients suffering from intermediate-risk or high-risk PE
as these risk groups are the main candidates for new treat-
ments. Furthermore, the embolus should be of autologous
blood to enable evaluation of thrombolytic agents. To
mimic the event of a large centrally located PE (the type
of PE most suitable for catheter-based interventions), the
thrombus needs to be large enough to lodge in the main
pulmonary arteries. Finally, the model needs to be well
characterized regarding RV function, systemic hemo-
dynamics, biochemical responses, visualization of embol-
isms in situ, and preferably allow for serial evaluations.
There are overall very few in vivo models of acute PE
and, to our knowledge, none that fulfills all of the criteria
above.14–22
We aimed to develop and characterize a model of cen-
trally located autologous intermediate-high-risk PE in pigs
suitable for evaluation of novel catheter and pharmaco-
logical therapies.
Methods
Animals
The study was approved by the Danish Animal Research
Inspectorate (license number: 2016-15-0201-00840) and was
conducted in accordance with institutional and national
guidelines for the ethical care of animals. Eight female
Danish Landrace pigs (60 kg) were used. Animals were
housed, handled, and transported according to the guide-
lines of the Danish Animal Research Inspectorate.
Criteria
The aim of this study was to develop a model of intermedi-
ate to high-risk acute PE, as defined according to the
European Society of Cardiology guidelines.3 The following
criteria needed to be met: hemodynamic and biochemical
signs of RV strain with a preserved systemic circulation
characterized by increased pulmonary artery pressures
(PAP); RV dilatation; decreased right ventricular ejection
fraction (RVEF); increased plasma levels of Troponin T
(TnT); but unchanged cardiac output (CO) and systolic
blood pressure. Second, to enable evaluations of catheter
directed therapies, the PE should remain intact after admin-
istration and be visualized in situ in the central pulmonary
arteries by magnetic resonance imaging (MRI).
Study design
Two consecutive PEs were administered to eight Danish
Landrace pigs (PE1 and PE2). All animals followed the
same protocol (Fig. 1) and served as their own controls.
Approximately 150min after induction of anesthesia, base-
line (BL) measurements were performed outside the MRI
scanner: ventilator settings and output were noted.
Invasive systemic blood pressures and heart rate were
noted. Venous and arterial blood samples were drawn and
transferred to the lab immediately. A right heart catheter-
ization (RHC) was performed, guided by continuous pres-
sure wave monitoring. Due to the slight magnetic properties
of the Swan-Ganz catheter, it was removed before the flat
bed was positioned in the scanner. Heart and lung MRI
Fig. 1. Study design (n¼ 8).
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scans were then performed. The duration of the evaluation
process was approximately 30min. At 180min, PE1 was
administered. After allowing for stabilization for 10 min,
the evaluation process was repeated. At 220min, PE2 was
administered and at 230min, the final evaluation was per-
formed. The pig was euthanized with an intravenous (IV)
injection of Pentobarbital (67mg/kg, Exagon vet, Richter
Pharma, Austria).
Anesthesia, instrumentation, and invasive pressures
The pigs were premedicated by subcutaneous injections of
Azaperone (2.2mg/kg, Stesnil, Elanco, USA) and
Midazolam (0.5mg/kg, Hameln Pharma, Germany) before
transport to the research facilities. Upon arrival, an IV
access was obtained in a vein on the ear. Anesthesia was
induced with an IV bolus injection of Etomidate
(0.5mg/kg, Hypnomidate, Janssen Pharmaceutical,
Belgium) and maintained with continuous IV infusion of
Fentanyl (5 mg/kg/h, Hameln Pharma, Germany) and
Propofol (2mg/kg/h, Propolipid, Fresnius Kabi,
Germany). The pigs were intubated (ID 7.5mm,
Unomedical, Malaysia) and ventilated by a mechanical ven-
tilator with tidal volume 8mL/kg, respiratory rate 16
breaths/min (adjusted to achieve an end tidal CO2
[ETCO2] 5.0–5.5) and no positive end-expiratory pressure.
The fraction of inspired oxygen was initially set to 1.0 to
compensate for the hypoxia during intubation, but reduced
to 0.3 after stabilization to mimic room air. All ventilation
settings were maintained unchanged throughout the experi-
ment. A pulse oximeter was attached to the ear to monitor
oxygen saturation. A bladder catheter (size 14) was inserted
to collect urine. To ensure normothermia, the pig was cov-
ered with a warming blanket (Bair Hugger, 3M, MN, USA)
and the temperature monitored by a rectal thermometer.
All vascular accesses were obtained using an ultrasound-
guided minimal-invasive approach. A 17-gauge Venflon can-
nula was used for vessel puncture to enable the introduction
of a guidewire. A small incision was made at the level of the
skin before a sheath was introduced over the wire. To avoid
interfering with the coagulation system, no heparin was
used. Instead, all vascular accesses were flushed regularly
with isotonic saline to avoid clotting. Three sheaths were
inserted. A 7-French (F) sheath was inserted in the left
external jugular vein for drawing of blood for the emboli
and for serial blood sampling. A 6-F sheath was inserted in
the left femoral artery for measurement of arterial blood
pressure and for serial arterial blood sampling. A 26-F
Dry-Seal sheath (Gore Medical, USA) was inserted in the
right external jugular vein guided by fluoroscopy. A 1.5-cm
incision was made in the skin and the underlying muscula-
ture, before the vessel was dilated with a 12-F sheath. The
26-F Dry-Seal sheath was introduced over the wire
(Amplatz extra stiff, 0.035’’, Mermaid Medical, Denmark)
to the superior vena cava at the level of the right atrium.
Additional to administration of emboli, the dry-seal port
was used for insertion of a Swan-Ganz catheter (7.5F,
CCOmbo, Edwards Lifescience, USA). RHCs were per-
formed using standard techniques. To avoid manipulating
or fragmenting the embolus or placing the catheter in an
obstructed segment hereby obtaining incorrect values, the
catheter was placed in the main pulmonary artery (PA)
and we did not perform wedging.
Creation and administering of pulmonary emboli
The emboli were created ex vivo using an autologous blood
sample. Immediately after achieving venous access 120mL
blood was drawn (replaced with 120mL of isotonic saline).
Then, 30mL blood was injected into 4.7500 plastic tubes
(only two were used, the other two served as a reserve). A
total of 0.1mL gadolinium contrast (279.3mg/mL,
Dotarem, Guerbet, France) was added and the tubes
were clamped at both ends to mix the gadolinium in the
blood. After hanging vertically for 3–4 h at room tempera-
ture, the samples divided into two phases: the supernatant
and the embolus. The supernatant was discarded and the
embolus placed on a clean swap to dry of excess fluids. As
we suspended the blood at a vertical position, the thrombus
took shape after the longitudinal cylindrical tube. By this
protocol, we were able to create very consistent cylindrical
emboli (1 20 cm) mimicking those that could be dislodged
in relation to deep venous thrombosis (Fig. 2). For admin-
istering, the embolus was transferred to another tube and
suspended in isotonic saline. This tube was connected to a
26-F Dry-Seal sheath in the right external jugular vein via a
cannula. A pressure bag with isotonic saline (200mmHg)
was attached to the distal end of the tube and the system
Fig. 2. Embolus. Photo illustrating a representative example of an embolus with rulers showing a diameter of 1 cm and length of 20 cm.
Pulmonary Circulation Volume 8 Number 1 | 3
was filled and emptied of air (Fig. 3, Video 1). When in
place, the saline flow carried the embolus en bloc through
the cannula, via the sheath to the right atrium. Afterwards
the saline flow was stopped and the cannula removed. The
embolus was then carried by the blood flow from the right
atrium, via the RV, to the PA and lodged as a PE. All iso-
tonic saline used for flushing, replacing of blood loss, and
infusion of anesthesia were recorded.
Magnetic Resonance Imaging
MRI was performed with a 1.5-T whole-body scanner
(Achieva dStream, Philips, Best, The Netherlands).
Animals were transported to the scanner with manual ven-
tilation. The ventilator and infusion pumps were placed in
the control room and connected to the pig via tube exten-
sion. An electrocardiogram as well as respiratory rate was
measured continuously to enable precise triggering. By
maintaining the exact location of pig on the flat bed, we
were able to use unaltered MRI projections enabling precise
serial measuring. Total scan time for all sequences after
injection of the embolus was about 20min.
Functional measures
All functional scans were performed at BL and after each of
the emboli. To measure RVEF as well as the volume of the
right and left ventricle, a stack with 14 slices of cine acqui-
sitions, encompassing the heart from base to apex in the
cardiac short-axis orientation, was acquired. A balanced
steady-state-free-precession (B-SSFP) pulse sequence was
used with a field of view (FOV) of 300 300mm, acquisition
matrix of 152 155, slice thickness was 8mm, and 30 heart
phases were acquired. To measure flow, right ventricular
stroke volume (RVSV), and cardiac output, a phase contrast
sequence was obtained from the RV outflow tract. FOV was
350 350mm, acquisition matrix was 288 288, slice thick-
ness was 8mm, and the velocity encoding parameter (Venc)
was 100 cm/s. All image analyses of functional parameters
were performed using the freely available software Segment
2.0 (Medviso, http://segment.heiberg.se). Volumes of the
RV was measured by manually drawing the endocardium
during end-diastole and end-systole on all slices encompass-
ing the heart. By drawing a region of interest at the cross-
sectioned PA in the phase-contrast scan, pulmonary flow
curves were obtained. After adjusting for eddy currents,
RVSV and CO were calculated. All analyses were performed
by a trained blinded investigator.
Pulmonary angiography
At BL, a three-dimensional (3D) B-SSFP scan was acquired
in the diastole to visualize the pulmonary vasculature. Slice
thickness was 3mm, FOV was 360 360 200mm, and
matrix was 256 256 66. To obtain images of the emboli
in situ, 3D diastolic scans with an inversion pulse (same
parameters as above) were performed both at BL and fol-
lowing injection of each embolus. To determine the optimal
inversion time, we performed a Look-Locker T1 mapping.
We chose the inversion time with the lowest signal for blood.
At this time, a weak signal was obtained from the myocar-
dium, while the emboli, containing Gadolinium, showed a
Fig. 3. Experimental set-up. A pig is lying on the flat bed in the MRI scanner. It is wrapped in plastic to avoid risk of contaminating the scanner. On
top of the pig is the coil. On the green cloth is the tube with the PE suspended in saline (black arrow). Attached are the cannula with a plastic
clamp (white arrow) and the MRI-safe pressure bag (dashed white arrow).
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high signal. A two-dimensional respiration navigator
method was used enabling scanning during free-breathing.23
Image analyses were performed using OsiriX (Pixmeo
SARL, Switzerland). The BL 3D scan with inversion pulse
was subtracted from the post-emboli scan, leaving only the
emboli. This scan was then merged with the BL 3D scan
enabling a 3D visualization of the emboli in situ.
Biochemical analyses
At each point of evaluation, a venous and arterial blood
sample was drawn and transported to the lab within
5min. The arterial sample was analyzed for partial pressures
of blood gasses and concentrations of electrolytes, lactate,
and glucose (ABL90 FLEX PLUS, Radiometer Medical,
Denmark). The venous blood sample was drawn in
Lithium Heparin tubes, centrifuged at 5000 RPM for
10min at 4C. Plasma was then collected and placed at
20C. Plasma samples were analyzed for levels of TnT, a
biomarker of RV strain, by a blinded investigator at the
Department of Clinical Biochemistry at Aarhus University
Hospital using a high sensitivity assay (Elecsys, Roche,
Basel, Switzerland). The predetermined cut-off value deter-
mined by the manufacturer and validated in a large multi-
center cohort of patients with acute PE.24
Statistics
The study was designed as repeated measures with a within-
subject variable. Each animal therefore served as its own
control. We used an ANOVA model with paired multiple
comparisons to test for mean differences between variables:
BL vs. PE1 and PE1 vs. PE2. Shapiro Wilks normality test
was used to test for normal distribution. Normally distrib-
uted data are presented as mean standard error of mean
(SEM). P< 0.05 were considered significant.
Results
Visualization of pulmonary embolism in situ
We obtained pulmonary angiographies at BL and after each
embolus by MRI and found that the emboli reached the
pulmonary vasculature without fragmenting (2/16 PEs did
fragment into smaller emboli, though still lodging centrally).
Emboli lodged centrally as either a saddle embolus (n¼ 3),
in the right PA (n¼ 8) or left PA (n¼ 5), and stretched down
to the segmental arteries (Fig. 4, Videos 2 and 3). Seven of
eight pigs had bilateral PEs. For a description of the loca-
tion of each PE see supplement (Table 1).
Hemodynamic signs of RV strain
PAPs increased twofold after administering the PEs (Fig. 5),
indicating a substantial increase in afterload. The RV
showed signs of strain after PE1 and even further after
PE2 as seen by increasing right ventricular end-diastolic
(RVEDV) and right ventricular end-systolic volumes
(RVESV) and with RVSV. This translated into a consider-
able decrease in RVEF (Fig. 5). A compensatory increase in
heart rate, however, prevented impairment of the systemic
circulation evident by an unaltered CO and systemic mean
arterial blood pressure (MAP) (Fig. 5). Despite an unaltered
MAP, we did observe an increase in diastolic blood pressure
after PE1 (mmHg, BL: 53.3 3.8 vs. PE1: 59.1 2.6,
P¼ 0.043) and a decline in pulse pressure with PE1 and
PE2 (mmHg, BL: 57.6 4.4, PE1: 52.0 6.6, PE2:
46.4 7.7, F(1.88,13.2)¼ 5.28, P¼ 0.02). This corresponded
well with the decreased RVSV measured by MRI.
Biochemical signs of RV strain
Plasma levels of TnT were elevated after PE1 compared
to BL (Fig. 6). After PE2, the concentration of TnT
Fig. 4. 3D MRI of pulmonary emboli in situ. (a) 3D MRI image illustrating a saddle embolus in situ. Notice that the embolus is still intact and
hinged on the pulmonary bifurcation. (b) Images depict a saddle embolus on slices from the main PA (top left) to the distal segmental arteries (low
right). (c) 3D MRI image illustrating bilateral PEs. Pes are colored yellow with white arrows.
LV, left ventricle; RV, right ventricle; Ao, aorta; POT, pulmonary outflow tract; RPA, right pulmonary artery; LPA, left pulmonary artery.
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surpassed the validated cut-off value for RV strain of
14 pg/mL (Fig. 6).
Gas exchange
As the ventilation settings were maintained constant
throughout the experiment, the animals were unable to
increase their ventilation minute volume in contrast to a
patient suffering from acute PE. While a constant minute
volume is not the normal physiological response, it allowed
us to indirectly evaluate the ventilation/perfusion mismatch
by the impaired gas exchange. ETCO2 was monitored
during the administering of the emboli. We found that the
ETCO2 decreased immediately after each embolus, but
within minutes it increased to levels even higher than BL.
We noted that the minimum value decreased with each
Fig. 5. Hemodynamic signs of RV strain. Data presented as mean SEM. *P< 0.05, yP< 0.05 for Anova analyses.
Table 1. Location of PE in situ.
Animal PE1 PE2 Bilateral
1 RPA to distal segmental arteries LPA to distal segmental arteries Yes
2 LPA to distal segmental arteries Right lower segmental arteries; fragmented Yes
3 RPA to both upper and lower RPA. Saddle to both RPA and LPA Yes
4 Saddle to both RPA and LPA RPA to both upper and lower RPA Yes
5 RPA to lower segmental arteries LPA to both upper and lower LPA Yes
6 RPA to lower segmental arteries LPA to lower segmental arteries Yes
7 Left lower segmental arteries; fragmented Saddle to both RPA and LPA Yes
8 Lower right segmental arteries RPA stretching to both upper and lower RPA No
RPA, right pulmonary artery; LPA, left pulmonary artery.
Fig. 6. Biochemical signs of RV strain. Data presented as mean SEM.
*P< 0.05, yP< 0.05 for Anova analyses, §P (one-sided)< 0.05 vs. cut-
off 14 pg/mL.
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embolus (Fig. 7). Partial arterial CO2 pressure increased sig-
nificantly while partial arterial O2 pressure decreased. Taken
together this corresponds well with an increasing ventila-
tion/perfusion mismatch causing an accumulation of arterial
CO2. This caused a respiratory acidosis as seen by the
decreasing arterial pH (Fig. 7).
Discussion
By administering two consecutive PEs in an in vivo porcine
model, we found a dose-dependent increase in both hemo-
dynamic and biochemical signs of RV strain with preserved
systemic circulation. The response of the animals to the PEs
was comparable to what is found for patients suffering from
intermediate-high-risk PE.3
To our knowledge, this is the first model to successfully
visualize an autologous contrast-enhanced PE by MRI. This
enables us to confirm the intact nature and central location
of the emboli in our model. For further interventional stu-
dies in this model, the in situ visualization may prove
important as it provides a precise evaluation of the degree
of residual emboli.
We aimed to develop a model of acute PE comparable to
intermediate-high-risk PE in patients. We found that the
injection of one embolus indeed caused RV strain compar-
able to that of intermediate-risk patients. PAPs increased
causing the RV to dilate. Despite the finding of a decrease
in RVSV and RVEF, CO was maintained by a compensa-
tory increase in heart rate. This physiological response is
similar to what is seen in patients suffering from intermedi-
ate-risk PE. In high-risk patients, however, the RV is unable
to overcome the afterload by increasing contractility and
heart rate; hence, CO and systemic blood pressure will
decrease. In current guidelines, systemic hypotension or
shock is therefore the criterion that differentiates high-risk
patients from patients at intermediate-risk of early death.
While the PAPs and RV strain increased further after the
second embolus in our model, the systemic circulation
remained uncompromised. Despite a further increase in
heart rate, the animals did not develop systemic hypoten-
sion. The animals did, however, show biochemical signs of
RV strain with levels of TnT above the cut-off value, making
the model comparable to patients suffering from
intermediate to high-risk PE.3 The pigs compensated well,
even when challenged by a massive thrombus burden. It is
well-known that the thrombus burden alone does not define
the outcome of a patient suffering from acute PE. Two
patients exposed to the same thrombus burden may show
very different clinical responses depending on their RV func-
tion. A PE of a given size can be fatal in an elderly patient
with co-morbidity, but may only cause mild symptoms in a
young and fit person. The fact that we have used young and
previously healthy animals may be a reason why they did
not show signs of compromised systemic circulation. In pilot
studies, we attempted to administer a third embolus, but
found it to cause uncontrollable hemodynamic collapse
and death. This underlines the narrow interval between
high-risk PE and fatal PE. A stable model of high-risk PE
in pigs with an acceptable variance and mortality rate may
therefore be difficult to develop.
This is, to our knowledge, the first experimental model of
massive centrally located autologous PE. The majority of
current experimental models of PE are ex vivo.13 Ex vivo
models are relevant for fast and cost-effective testing of
novel treatment options in the early development phase.
Before implementing new treatment strategies in patients,
it is, however, pivotal to evaluate the efficacy and safety in
a setting more comparable to human physiology. Larger
animal models may provide this opportunity. The very few
existing in vivo models use predominantly artificial mater-
ials such as plastic spheres or balloons to obstruct the
PAs.16–20 The evaluation of novel treatments including
thrombolytics is therefore not possible in these models.
Furthermore, the evaluation of catheter directed therapies
would be questionable, as the material removed would differ
significantly from a real embolus. A few models have used
autologous thrombus made ex vivo as in our model.14,15,21
However, emboli in these studies are much smaller in size,
and though these studies have not described the location of
the emboli in situ, we can presume that they would travel
distally in the pulmonary circulation. These models may be
suitable for evaluation of pharmacological treatment, while
a more proximal location of the emboli would be more
suited for the evaluation of catheter-directed therapies.
The autologous nature, the central location and the in situ
visualization of the PE, makes our model suitable for the
Fig. 7. Gas exchange. Data presented as mean SEM. *P< 0.05, yP< 0.05 for Anova analyses.
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evaluation of a wide range of therapies. Furthermore, the
very comprehensive and precise hemodynamic characteriza-
tion of the model ensures a controlled and sensitive
evaluation.
Limitations
The model is indeed an animal model and we cannot rule
out inter-species differences. The pig has, however, previ-
ously proven a valid species for translatable cardiovascular
models due to its anatomy, size and hemodynamics.
Despite achieving an autologous embolus with a size and
shape similar to that in patients, it was however still created
ex vivo. Emboli in patients are often formed in the lower
extremity veins where it is exposed to continuous substrates
and inflammatory components. A recent study compared ex
vivo thrombi with thrombi from thrombectomies and found
the latter to be more heterogeneous and contain more extra-
cellular matrix.25 The same study, however, showed that
adding thrombin did not increase the fraction of extracellu-
lar matrix. Therefore, we chose spontaneous coagulation in
our model. Due to the homogeneous nature and low frac-
tion of extracellular material of the embolus in this model
we believe that it corresponds to a fresh thrombus in
patients. As it was rigid and proved intact after injection,
we find it suitable for evaluation of both catheter-based and
fibrinolytic therapies. An experimental model of a more
chronic thrombus created in vivo in the inferior vena cava
has been developed.22 In this chronic model, it was, how-
ever, not possible to control the size of the thrombus,
thereby creating a large variance in the model.
Furthermore, the model is time-consuming and logistically
challenging.
We chose to use the combination of IV Fentanyl and
Propofol as analgesia and anesthesia in this model. In
pilot studies, we used inhaled Sevoflurane, but found that
the inherent ventilation/perfusion mismatch caused by the
emboli caused differences in anesthetic depth and introduced
bias. We therefore chose IV infusions and found that the
Propofol/Fentanyl combination in the lowest possible con-
centrations was the most stable option. We performed
repeat measures and used the same low dose of IV anes-
thetics throughout the protocol to minimize bias.
Hemodynamic measures may, however, be influenced by
anesthesia which should be taken into consideration in the
interpretation of the results from this study. We performed
serial MRI scans in this protocol. This can be a challenge
due to availability and cost. MRI, compared to the more
traditional CT or echocardiography, however, provides
important additional data. Most importantly, the phase-
contrast images provide the golden standard of cardiac
output measures, which is pivotal for the evaluations of
the RV function.26 Furthermore, the thin slices of the RV
enable precise measures of RV volumes, important to deter-
mine RV strain. Finally, the novel 3D angiographies with
contrast-enhanced emboli provides excellent images to
determine the location of the emboli. In future studies
using this model, echocardiography could potentially be
an alternative to MRI where this modality is unavailable.
One should, however, be aware of the challenges of perform-
ing trans-thoracic echocardiography in pigs. The pointed
anatomy of the pig chest impairs the quality of obtained
images significantly. Trans-esophageal echocardiography
may, however, be an alternative to MRI.
Conclusion
We succeeded in developing an in vivo model of central
autologous acute PE in pigs. To our knowledge, this is the
first model to successfully visualize an autologous contrast-
enhanced PE on MRI. By administering two consecutive
PE, we found a dose-dependent increase in RV strain with
preserved systemic circulation. The model is comparable to
patients suffering from intermediate-high-risk PE and may
prove a useful tool in the preclinical evaluation of novel
catheter-directed and pharmacological therapies for these
patients.
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